Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parcel
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Parcel** is an oral fixed-dose analgesic and antimigraine product containing dihydroergotamine mesylate, paracetamol, and caffeine. Dihydroergotamine is an ergot-derived serotonergic agonist that promotes cranial vasoconstrictive antimigraine activity; paracetamol provides analgesia; and caffeine acts as an analgesic adjuvant. Each coated tablet contains dihydroergotamine mesylate 1 mg, paracetamol 450 mg, and caffeine 40 mg. It has been used for symptomatic treatment of headache and migraine and was evaluated in a Phase 3 non-inferiority study in tension-type headache. ([consultaremedios.com.br](https://consultaremedios.com.br/parcel/bula))
- Brand names
- Parcel
- Other names
- cafeína + mesilato de diidroergotamina + paracetamoldihydroergotamine mesylate + paracetamol + caffeine
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)
Beyond the preview
Go deeper on Parcel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Parcel.